Prevention of NSF is critical, particularly in high-risk populations such as cancer patients with renal impairment. Key preventive measures include:
Screening for kidney function before administering GBCAs Using the lowest effective dose of GBCAs Considering alternative imaging modalities that do not require contrast agents Hydrating patients well before and after contrast administration Monitoring patients closely for any early signs of NSF
